| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1879 | |
| Phytochemical name or plant extracts | Vernomelitensin | |
| PMID | 27311895 | |
| Literature evidence | In addition, 5 exhibited significant antiproliferative activities against HeLa and MDA-MB-231 cells, with IC50 values ranging from 1.90 to 2.20μM. | |
| IUPAC name | (3aR,4S,7R,7aR)-6-ethenyl-2,3-dimethylidene-7-(3-oxoprop-1-en-2-yl)-octahydro-1-benzofuran-4-yl 2-(hydroxymethyl)prop-2-enoate | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene lactones | |
| Source of phytochemicals or plant Extracts | Vernonia anthelmintica, Vernonia guineensis Benth | |
| Geographical availability | Vernonia anthelmintica - Afghanistan, Botswana, China South-Central, India, Kenya, Laos, Malawi, Mozambique, Myanmar, Namibia, Nepal, Pakistan, Sri Lanka, Tanzania, Uganda, Vietnam, West Himalaya, Zambia, Zaïre, Zimbabwe Vernonia guineensis - Angola, Benin, Burkina, Cameroon, Central African Repu, Chad, Congo, Gabon, Guinea, Gulf of Guinea Is., Ivory Coast, Liberia, Mali, Nigeria, Sierra Leone, Sudan, Togo, Zambia, Zaïre | |
| Plant parts | Seeds, Leaves | |
| Other cancers | Breast cancer, Colon cancer, Leukemia, Lung cancer, Skin cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Cervical cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 0.367 ±0.030 μM against MDA-MD-231 1.56 ± 0.960 μM against MCF-7 | |
| Potency | NA | |
| Cell line/ mice model | MDA-MB-231, MCF-7, HCT-116, HL-60, A549, A375, OVCAR3, PC-3, DU-145 | |
| Additional information | Exhibits anti-proliferative acitivty in the mentioned cell lines Shows strong antiproliferative activities against three human cancer cell lines (A549, HeLa, and MDA-MB-231) | |
| PubChem ID | NA | |
| Additional PMIDs | 23376285 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:257826-1 https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:258475-1 | |
| Safety | NA |